Thermo Fisher Scientific CAHM1 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000-1:2,000

-

Immunohistochemistry (IHC)

1:1,000-1:2,000

-

Miscellaneous PubMed (Misc)

-

View 1 publication 1 publication

Product Specifications

Species Reactivity

Mouse, Rat

Published species

Not Applicable

Host/Isotype

Rabbit / Ig

Class

Polyclonal

Type

Antibody

Immunogen

A synthetic peptide from aa region 250-300 of mouse CAHM1 conjugated to blue carrier protein was used as the antigen if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CALHM1,uniProtId:D3Z291-1,ncbiNodeId:10090,antigenRange:250-300,antigenLength:348,antigenImageFileName:OSC00325W-100UL_CALHM1_D3Z291-1_Rabbit.svg,antigenImageFileNamePDP:OSC00325W-100UL_CALHM1_D3Z291-1_Rabbit_PDP.jpeg,sortOrder:2}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

Conc. Not Determined

Storage buffer

whole serum

Contains

no preservative

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. Glycerol (1:1) may be added for added stability.

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Reconstitute in 100 µL of sterile water. Centrifuge to remove any insoluble material.

The antigen shares 97% identity with the rat sequence.

Specificity of this antibody: CAHM1.

Target Information

Alzheimers disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP). The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.